메뉴 건너뛰기




Volumn 17, Issue 5, 2004, Pages 411-416

Use of low molecular weight heparins and glycoprotein IIb/IIIa inhibitors in patients with chronic kidney disease

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CY 222; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN; TIROFIBAN;

EID: 7044263050     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0894-0959.2004.17351.x     Document Type: Review
Times cited : (12)

References (43)
  • 1
    • 0034124811 scopus 로고    scopus 로고
    • Survival after acute myocardial infarction in patients with end-stage renal disease: Results from the cooperative cardiovascular project
    • Chertow GM, Normand SL, Silva LR, McNeil BJ: Survival after acute myocardial infarction in patients with end-stage renal disease: results from the cooperative cardiovascular project. Am J Kidney Dis 35:1044-1051, 2000
    • (2000) Am J Kidney Dis , vol.35 , pp. 1044-1051
    • Chertow, G.M.1    Normand, S.L.2    Silva, L.R.3    McNeil, B.J.4
  • 2
    • 0036711313 scopus 로고    scopus 로고
    • Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention
    • Fox KA, Antman EM, Cohen M, Bigonzi F, ESSENCE/TIMI 11B Investigators: Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention. Am J Cardiol 90:477-482, 2002
    • (2002) Am J Cardiol , vol.90 , pp. 477-482
    • Fox, K.A.1    Antman, E.M.2    Cohen, M.3    Bigonzi, F.4
  • 3
    • 0037438875 scopus 로고    scopus 로고
    • Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention
    • Wong GC, Giugliano RP, Antman EM: Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA 289:331-342, 2003
    • (2003) JAMA , vol.289 , pp. 331-342
    • Wong, G.C.1    Giugliano, R.P.2    Antman, E.M.3
  • 4
    • 2242477091 scopus 로고
    • Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
    • The EPIC Investigation
    • Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 330:956-961, 1994
    • (1994) N Engl J Med , vol.330 , pp. 956-961
  • 5
    • 1842369101 scopus 로고    scopus 로고
    • Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
    • The EPILOG Investigators
    • Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 336:1689-1696, 1997
    • (1997) N Engl J Med , vol.336 , pp. 1689-1696
  • 6
    • 0035897893 scopus 로고    scopus 로고
    • Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial
    • Simoons ML, GUSTO IV-ACS Investigators: Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 357:1915-1924, 2001
    • (2001) Lancet , vol.357 , pp. 1915-1924
    • Simoons, M.L.1
  • 7
    • 0030858230 scopus 로고    scopus 로고
    • Low-molecular-weight heparins
    • Weitz JI: Low-molecular-weight heparins. N Engl J Med 337:688-698, 1997
    • (1997) N Engl J Med , vol.337 , pp. 688-698
    • Weitz, J.I.1
  • 8
    • 0022559153 scopus 로고
    • Pharmacokinetic studies of standard heparin and low molecular weight heparin in patients with chronic renal failure
    • Follea G, Laville M, Pozet N, Dechavanne M: Pharmacokinetic studies of standard heparin and low molecular weight heparin in patients with chronic renal failure. Haemostasis 16:147-151, 1986
    • (1986) Haemostasis , vol.16 , pp. 147-151
    • Follea, G.1    Laville, M.2    Pozet, N.3    Dechavanne, M.4
  • 12
    • 0036272018 scopus 로고    scopus 로고
    • Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes
    • Becker RC, Spencer FA, Gibson M, Rush JE, Sanderink G, Murphy SA, Ball SP, Elliott MA: Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 143:753-759, 2002
    • (2002) Am Heart J , vol.143 , pp. 753-759
    • Becker, R.C.1    Spencer, F.A.2    Gibson, M.3    Rush, J.E.4    Sanderink, G.5    Murphy, S.A.6    Ball, S.P.7    Elliott, M.A.8
  • 14
    • 0036049628 scopus 로고    scopus 로고
    • Prolonged anti-factor Xa level in a patient with moderate renal insufficiency receiving enoxaparin
    • Bastani B, Gonzalez E: Prolonged anti-factor Xa level in a patient with moderate renal insufficiency receiving enoxaparin. Am J Nephrol 22:403-404, 2002
    • (2002) Am J Nephrol , vol.22 , pp. 403-404
    • Bastani, B.1    Gonzalez, E.2
  • 15
    • 0037049342 scopus 로고    scopus 로고
    • Is impaired renal function a contraindication to the use of low-molecular-weight heparin?
    • Nagge J, Crowther M, Hirsh J: Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 162:2605-2609, 2002
    • (2002) Arch Intern Med , vol.162 , pp. 2605-2609
    • Nagge, J.1    Crowther, M.2    Hirsh, J.3
  • 17
    • 0025779064 scopus 로고
    • Pharmacokinetics of a very low molecular weight heparin in chronic renal failure
    • Hory B, Claudet MH, Magnette J, Bechtel P, Bayrou B: Pharmacokinetics of a very low molecular weight heparin in chronic renal failure. Thromb Res 63:311-317, 1991
    • (1991) Thromb Res , vol.63 , pp. 311-317
    • Hory, B.1    Claudet, M.H.2    Magnette, J.3    Bechtel, P.4    Bayrou, B.5
  • 18
    • 0025945703 scopus 로고
    • Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure
    • Goudable C, Saivin S, Houin G, Sie P, Boneu B, Tonthat H, Suc JM: Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure. Nephron 59:543-545, 1991
    • (1991) Nephron , vol.59 , pp. 543-545
    • Goudable, C.1    Saivin, S.2    Houin, G.3    Sie, P.4    Boneu, B.5    Tonthat, H.6    Suc, J.M.7
  • 19
    • 0033923679 scopus 로고    scopus 로고
    • Enoxaparin and bleeding complications: A review in patients with and without renal insufficiency
    • Gerlach AT, Pickworth KK, Seth SK, Tanna SB, Barnes JF: Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 20:771-775, 2000
    • (2000) Pharmacotherapy , vol.20 , pp. 771-775
    • Gerlach, A.T.1    Pickworth, K.K.2    Seth, S.K.3    Tanna, S.B.4    Barnes, J.F.5
  • 20
    • 0035210952 scopus 로고    scopus 로고
    • Enoxaparin-associated severe retroperitoneal bleeding and abdominal compartment syndrome: A report of two cases
    • Dabney A, Bastani B: Enoxaparin-associated severe retroperitoneal bleeding and abdominal compartment syndrome: a report of two cases. Intensive Care Med 27:1954-1957, 2001
    • (2001) Intensive Care Med , vol.27 , pp. 1954-1957
    • Dabney, A.1    Bastani, B.2
  • 21
    • 0033624537 scopus 로고    scopus 로고
    • Enoxaparin associated with huge abdominal wall hematomas: A report of two cases
    • Antonelli D, Fares L 2nd, Anene C: Enoxaparin associated with huge abdominal wall hematomas: a report of two cases. Am Surg 66:797-800, 2000
    • (2000) Am Surg , vol.66 , pp. 797-800
    • Antonelli, D.1    Fares II, L.2    Anene, C.3
  • 22
    • 0035056845 scopus 로고    scopus 로고
    • Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin
    • Busby LT, Weyman A, Rodgers GM: Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin. Am J Hematol 67:54-56, 2001
    • (2001) Am J Hematol , vol.67 , pp. 54-56
    • Busby, L.T.1    Weyman, A.2    Rodgers, G.M.3
  • 24
    • 0035522327 scopus 로고    scopus 로고
    • Choosing a parenteral anticoagulant agent
    • Diuguid DL: Choosing a parenteral anticoagulant agent. N Engl J Med 345:1340-1342, 2001
    • (2001) N Engl J Med , vol.345 , pp. 1340-1342
    • Diuguid, D.L.1
  • 25
    • 0033034039 scopus 로고    scopus 로고
    • Outpatient treatment of deep vein thrombosis: Translating clinical trials into practice
    • Dunn AS, Coller B: Outpatient treatment of deep vein thrombosis: translating clinical trials into practice. Am J Med 106:660-669, 1999
    • (1999) Am J Med , vol.106 , pp. 660-669
    • Dunn, A.S.1    Coller, B.2
  • 26
    • 0035142879 scopus 로고    scopus 로고
    • Dosing and monitoring of low-molecular-weight heparins in special populations
    • Duplaga BA, Rivers CW, Nutescu E: Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy 21:218-234, 2001
    • (2001) Pharmacotherapy , vol.21 , pp. 218-234
    • Duplaga, B.A.1    Rivers, C.W.2    Nutescu, E.3
  • 29
    • 0037485598 scopus 로고    scopus 로고
    • Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: Analysis from the ESSENCE and TIMI 11B studies
    • Spinier SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM, ESSENCE and TIMI 11B Investigators: Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 146:33-41, 2003
    • (2003) Am Heart J , vol.146 , pp. 33-41
    • Spinier, S.A.1    Inverso, S.M.2    Cohen, M.3    Goodman, S.G.4    Stringer, K.A.5    Antman, E.M.6
  • 30
    • 0041358575 scopus 로고    scopus 로고
    • Review of antithrombotic agents used for acute coronary syndromes in renal patients
    • Fernandez JS, Sadaniantz BT, Sadaniantz A: Review of antithrombotic agents used for acute coronary syndromes in renal patients. Am J Kidney Dis 42:446-455, 2003
    • (2003) Am J Kidney Dis , vol.42 , pp. 446-455
    • Fernandez, J.S.1    Sadaniantz, B.T.2    Sadaniantz, A.3
  • 31
    • 0345173465 scopus 로고    scopus 로고
    • West Point, PA: Merck and Co., Inc.
    • Tirofiban package insert. West Point, PA: Merck and Co., Inc.
    • Tirofiban Package Insert
  • 32
    • 0034721399 scopus 로고    scopus 로고
    • Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
    • Bhatt DL, Topol EJ: Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 284:1549-1558, 2000
    • (2000) JAMA , vol.284 , pp. 1549-1558
    • Bhatt, D.L.1    Topol, E.J.2
  • 34
    • 0042165874 scopus 로고    scopus 로고
    • Platelet glycoprotein IIb/IIIa inhibition with eptifibatide: Prolongation of inhibition of aggregation in acute renal failure and reversal with hemodialysis
    • Sperling RT, Pinto DS, Ho KK, Carrozza JP Jr: Platelet glycoprotein IIb/IIIa inhibition with eptifibatide: prolongation of inhibition of aggregation in acute renal failure and reversal with hemodialysis. Cathet Cardiovasc Interv 59:459-462, 2003
    • (2003) Cathet Cardiovasc Interv , vol.59 , pp. 459-462
    • Sperling, R.T.1    Pinto, D.S.2    Ho, K.K.3    Carrozza Jr., J.P.4
  • 35
    • 18744392239 scopus 로고    scopus 로고
    • Bleeding associated with eptifibatide targeting higher risk patients with acute coronary syndromes: Incidence and multivariate risk factors
    • Rasty S, Borzak S, Tisdale JE: Bleeding associated with eptifibatide targeting higher risk patients with acute coronary syndromes: incidence and multivariate risk factors. J Clin Pharmacol 42:1366-1373, 2002
    • (2002) J Clin Pharmacol , vol.42 , pp. 1366-1373
    • Rasty, S.1    Borzak, S.2    Tisdale, J.E.3
  • 36
    • 0037420072 scopus 로고    scopus 로고
    • Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors
    • Freeman RV, Mehta RH, Al Badr W, Cooper JV, Kline-Rogers E, Eagle KA: Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 41:718-724, 2003
    • (2003) J Am Coll Cardiol , vol.41 , pp. 718-724
    • Freeman, R.V.1    Mehta, R.H.2    Al Badr, W.3    Cooper, J.V.4    Kline-Rogers, E.5    Eagle, K.A.6
  • 37
    • 0037083099 scopus 로고    scopus 로고
    • Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab
    • Frilling B, Zahn R, Fraiture B, Mark B, Donges K, Becker T, Siegler KE, Seidl K, Rustige J, Senges J: Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab. Am J Cardiol 89:450-452, 2002
    • (2002) Am J Cardiol , vol.89 , pp. 450-452
    • Frilling, B.1    Zahn, R.2    Fraiture, B.3    Mark, B.4    Donges, K.5    Becker, T.6    Siegler, K.E.7    Seidl, K.8    Rustige, J.9    Senges, J.10
  • 41
    • 0037150156 scopus 로고    scopus 로고
    • Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial
    • Januzzi JL Jr, Snapinn SM, DiBattiste PM, Jang IK, Theroux P: Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation 105:2361-2366, 2002
    • (2002) Circulation , vol.105 , pp. 2361-2366
    • Januzzi Jr., J.L.1    Snapinn, S.M.2    DiBattiste, P.M.3    Jang, I.K.4    Theroux, P.5
  • 42
    • 0037118664 scopus 로고    scopus 로고
    • Platelet glycoprotein IIb/IIIa inhibitors: Recognition of a two-edged sword?
    • Quinn MJ, Plow EF, Topol EJ: Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation 106:379-385, 2002
    • (2002) Circulation , vol.106 , pp. 379-385
    • Quinn, M.J.1    Plow, E.F.2    Topol, E.J.3
  • 43
    • 0142074359 scopus 로고    scopus 로고
    • Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: Appropriate interpretation of the guidelines
    • Antman EM: Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines. Am Heart J 146(suppl 4):S18-S22, 2003
    • (2003) Am Heart J , vol.146 , Issue.4 SUPPL.
    • Antman, E.M.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.